Rationale and Design of the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension

American Journal of Hypertension

Volumn 17, Issue 9, 2004, Pages 793-801

  Jamerson, Kenneth A ^a   Bakris, George L ^b   Wun, Chuan Chuan ^c   Dahlöf, Björn ^d   Lefkowitz, Martin ^c   Manfreda, Sheryl ^c   Pitt, Bertram ^a   Velazquez, Eric J ^e   Weber, Michael A ^a,f  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

combination therapy; hypertension; Randomized controlled trial

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EUROPE; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS;

EID: 4444380286     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.05.004     Document Type: Article

References (36)

1. R. Collins, S. MacMahon Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease Br Med J 50 1994 272 298
2. J. Stamler, R. Stamler, J.D. Neaton Blood pressure, systolic and diastolic, and cardiovascular risks Arch Intern Med 153 1993 598 615
3. S. Lewington, R. Clarke, N. Qizilbash, R. Peto, R. Collins Prospective Studies Collaboration Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 2002 1903 1913
4. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JAMA 289 2003 2560 2572
5. L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlff, D. Elmfeldt, S. Julius, J. Mnard, K.H. Rahn, H. Wedel, S. Westerling HOT Study Group Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension principal results of the Hypertension Optimal Treatment (HOT) randomized trial Lancet 351 1998 1755 1762
6. UK Prospective Diabetes Study Group Tight BP control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38 Br Med J 317 1998 703 713
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
8. L.M. Prisant, M.R. Weir, V. Papademetriou, M.A. Weber, I.A. Adegbile, D. Alemayehu, M.P. Lefkowitz, A.A. Carr Low dose drug combination therapy an alternative first line approach to hypertension treatment Am Heart J 130 1995 359 366
9. F.H. Messerli Combinations in the treatment of hypertension ACE inhibitors and calcium antagonists Am J Hypertens 12 1999 86S 90S
10. J.G. Douglas, G.L. Bakris, M. Epstein, K.C. Ferdinand, C. Ferrario, J.M. Flack, K.A. Jamerson, W.E. Jones, J. Haywood, R. Maxey, E.O. Ofili, E. Saunders, E.L. Schiffrin, D.A. Sica, J.R. Sowers, D.G. Vidt Management of high blood pressure in African Americas. Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Arch Intern Med 163 2003 525 541
11. European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension J Hypertens 21 2003 1011 1053
12. L. Hansson, T. Hedner, P. Lund-Johansen, S.E. Kjeldsen, L.H. Lindholm, J.O. Syvertsen, J. Lanke, U. de Faire, B. Dahlf, B.E. Karlberg Randomized trial of effects of calcium antagonists compared with diuretics and beta blockers on cardiovascular morbidity and mortality in hypertension the Nordic Diltiazem (NORDIL) study Lancet 356 2000 359 365
13. J.A. Staessen, R. Fagard, L. Thijs, H. Celis, G.G. Arabidze, W.H. Birkenhager, C.J. Bulpitt, P.W. de Leeuw, C.T. Dollery, A.E. Fletcher, F. Forette, G. Leonetti, C. Nachev, E.T. OBrien, J. Rosenfeld, J.L. Rodicio, J. Tuomilehto, A. Zanchetti Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension Lancet 350 1997 757 764
14. H.R. Black, W.J. Elliot, G. Grandits, P. Grambsch, T. Lucente, W.B. White, J.D. Neaton, R.H. Grimm Jr, L. Hansson, Y. Lacourciere, J. Muller, P. Sleight, M.A. Weber, G. Williams, J. Wittes, A. Zanchetti, R.J. Anders CONVINCE Research Group Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial JAMA 289 2003 2073 2082
15. L.M. Wing, C.M. Reid, P. Ryan, L.J. Beilin, M.A. Brown, G.L. Jennings, C.I. Johnston, J.J. McNeil, G.J. Macdonald, J.E. Marley, T.O. Morgan, M.J. West Second Australian National Blood Pressure Study Group A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for the treatment of hypertension in the elderly N Engl J Med 348 2003 583 592
16. Blood Pressure Lowering Treatment Trialists Collaboration Effects of ACE inhibitors, calcium antagonists, and other blood-pressuring-lowering drugs: results of prospectively designed overviews of randomized trials Lancet 356 2000 1955 1964
17. E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohode The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy The Collaborative Study Group. N Engl J Med 329 1993 1456 1462
18. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H.H. Parving, G. Remuzzi, S.M. Snapinn, Z. Zhang, S. Shahinfar RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Eng J Med 345 2001 861 869
19. B. Dahlf, R.B. Devereux, S.E. Kjeldsen, S. Julius, U. Beevers de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, L.H. Lindholm, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel LIFE study group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomized trial against atenolol Lancet 359 2002 996 1003
20. M.A. Weber, J.M. Neutel, W.H. Frishman Combination drug therapy W.H. Frishman E.H. Sonnenblick D.A. Sica Cardiovascular Pharmacotherapeutics 2nd ed 2003 McGraw-Hill New York 335 368
21. B.A. Scholkens, W. Landgraf ACE inhibition and atherogenesis Can J Physiol Pharmacol 80 2002 354 359
22. Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients N Engl J Med 342 2000 145 153
23. E.L. Schiffrin, L.Y. Deng, P. Larochelle Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin converting enzyme inhibitor Comparison with effects of beta blocker. Am J Hypertens 8 1995 229 236
24. B. Pitt, R.P. Byington, C.D. Furberg, D.B. Hunninghake, G.B.J. Mancini, M.E. Miller, W. Riley Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events Circulation 102 2000 1503 1510
25. R.P. Mason Mechanisms of atherosclerotic plaque stabilization for the lipophilic calcium antagonist amlodipine Am J Cardiol 88 Suppl 2001 2M 6M
26. E.L. Schiffrin, L.Y. Deng Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist J Hypertens 14 1996 1247 1255
27. S. Taddei, A. Virdis, L. Ghiadoni, I. Sudano, A. Salvetti Antihypertensive drugs and reversing of endothelial dysfunction in hypertension Curr Hypertens Reports 2 2000 64 70
28. N.K. Thybo, N. Stephens, A. Cooper, C. Aalkjaer, A.M. Heagerty, M.J. Mulvany Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension Hypertension 25 1995 474 481
29. I. Sihm, A.P. Schroeder, C. Aalkjaer, M. Holm, B. Morn, M. Mulvany, K. Thygesen, O. Lederballe The relation between peripheral vascular structure, left ventricular hypertrophy and ambulatory blood pressure in essential hypertension Am J Hypertens 8 1995 987 996
30. E.L. Schiffrin, J.B. Park, H.D. Intengan, R.M. Touyz Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan Circulation 101 2000 1653 1659
31. X. Zhang, X. Xu, A. Nasjletti, T.H. Hintze Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels J Cardiovasc Pharmacol 35 2000 195 202
32. J.M. Neutel, D.H.G. Smith, M.A. Weber A comparison of the effects of amlodipine 5 mg/benazerpril 20 mg combination therapy to component monotherapy on arterial distensibility and left ventricular hypertrophy in patients with mild to moderate hypertension Am J Hypertens 15 2002 166A
33. Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance Biometrika 75 1988 800 802
34. Y. Hochberg, Y. Benjamini More powerful procedures for multiple significance testing Stat Med 9 1990 811 818
35. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) JAMA 265 1991 3255 3264
36. M.A. Weber The ALLHAT Report a case of information and misinformation J Clin Hypertens 5 2003 9 13